First Steps to a Healthier Future
Worldwide, thousands of children are born with rare genetic conditions that severely affect their quality of life. This evening reception brought together senior leaders from healthcare, academia, industry and charities to celebrate and discuss the first steps of the Greek Genome Project - a pioneering genomic sequencing programme in Greece. Using whole genome sequencing, the project aims to diagnose diseases and identify treatment options before symptoms begin, a major advance over current practices that focus on children who are already critically ill.
Find out more about our work to support this important initiative with our partner Plumcare RWE in our press release and watch our highlights video from the event.
Over 65 senior representatives from Greek government, healthcare, academia, industry and patient groups came together to celebrate the first steps of the Greek genome project. Co-hosted by Lifebit with our partner Plumcare RWE, the event was an opportunity to learn about the ambitious goals of the programme.
The agenda included talks from leaders in Greek government and healthcare, genetic scientists and clinicians, bioinformaticians and national patient groups.
Dr Maria Dunford, Lifebit’s CEO explained how the sensitive genomic data would be held securely and safely and made available for research to enable new treatments for rare diseases.
Read our press coverage: Article in Protothema (Greek national newspaper)
Lifebit will provide the platform that will give safe access to the data so they can be used for diagnosis as well as drug discovery insights.
Karageorgi Servias 4
Syntagma Square, Athens
105 62
Over 65 senior representatives from Greek government, healthcare, academia, industry and patient groups came together to celebrate the first steps of the Greek genome project. Co-hosted by Lifebit with our partner Plumcare RWE, the event was an opportunity to learn about the ambitious goals of the programme.
The agenda included talks from leaders in Greek government and healthcare, genetic scientists and clinicians, bioinformaticians and national patient groups.
Dr Maria Dunford, Lifebit’s CEO explained how the sensitive genomic data would be held securely and safely and made available for research to enable new treatments for rare diseases.
Read our press coverage: Article in Protothema (Greek national newspaper)
″Lifebit will provide the platform that will give safe access to the data so they can be used for diagnosis as well as drug discovery insights. ″
Karageorgi Servias 4
Syntagma Square, Athens
105 62
More like this
Lifebit is proud to sponsor BiotechX Europe in Basel, Switzerland, on 9-10 October 2024.
Join the Lifebit team at this event designed for leaders in healthcare and pharma to share the latest innovations in precision medicine.